Halozyme Therapeutics (FRA:RV7) Pre-Tax Income : €362.5 Mil (TTM As of Mar. 2024)

Halozyme Therapeutics Pre-Tax Income Chart

Halozyme Therapeutics Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Pre-Tax Income		Get a 7-Day Free Trial					-65.03	106.29	219.94	234.98	319.42

Halozyme Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Pre-Tax Income	Get a 7-Day Free Trial															48.79	85.98	95.35	92.78	88.35

Competitive Comparison of Halozyme Therapeutics's Pre-Tax Income

For the Biotechnology subindustry, Halozyme Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Halozyme Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Halozyme Therapeutics's Pre-Tax Income falls into.

Halozyme Therapeutics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Halozyme Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Halozyme Therapeutics's Pretax Income for the quarter that ended in Mar. 2024 is calculated as

Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €362.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halozyme Therapeutics  (FRA:RV7) Pre-Tax Income Explanation

Halozyme Therapeutics's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

During the past 13 years, Halozyme Therapeutics's highest Pretax Margin was 56.06%. The lowest was -90.76%. And the median was -2.20%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halozyme Therapeutics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Halozyme Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Halozyme Therapeutics (FRA:RV7) Business Description